With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Novo Nordisk (NYSE:NVO) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 15, Novo ...

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Shares of Novo Nordisk (NVO) are rising early Monday after the US Food and Drug Administration approved Wegovy to treat ...

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...